# Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration

> **NCT01033721** · PHASE1 · COMPLETED · sponsor: **Paloma Pharmaceuticals, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** Palomid 529

## Key facts

- **NCT ID:** NCT01033721
- **Lead sponsor:** Paloma Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2012-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01033721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01033721, "Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01033721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*